PMVP - Pmv Pharmaceuticals Inc logo

PMVP

Pmv Pharmaceuticals Inc

Rev —top 1%5Y
Hold

PMV Pharmaceuticals develops small molecule therapies targeting p53 mutations and related cancers. The company is focused on clinical-stage treatments, including rezatapopt, for tumor agnostic diseases, primarily in the U.S. market.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $37today

Score Overview

1 Year
Score
Net Growth-0.77%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-35.44%
Net Trend40%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-127.48%
Net Trend33%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Pmv Pharmaceuticals Inc fundamental performance

Across Pmv Pharmaceuticals Inc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 34M to -$ 77M. Revenue increased in 0% of the years measured; net income in 33%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.26
1 Year2025-08-12
$ 1.42-11.27%
5 Years2021-08-12
$ 34.22-96.32%
All Time2020-09-25
$ 37.51-96.64%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 78M$ 93M
2025$ 0.00-$ 77M$ 112M
2024$ 0.00-$ 58M$ 169M
2023$ 0.00-$ 68M$ 203M
2022$ 0.00-$ 73M$ 241M
2021$ 0.00-$ 57M$ 297M
IPO2020$ 0.00-$ 34M$ 361M

Explore beyond PMVP

You're looking at Pmv Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies